Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Opinions Heard from
May 15, 2006
- Torii: Transfer of TachoComb Drives Down Sales
May 15, 2006
- JMA Reluctantly Accepts Healthcare Reform Bill
May 15, 2006
- Schering-Plough's Temodar
May 15, 2006
- 15% of Prescriptions Allow
May 15, 2006
- Development of 5 Unapproved Drugs Recommended
May 15, 2006
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
May 15, 2006
- Korosho Presents Draft Vision for Vaccine Industry
May 15, 2006
- SERVEY
May 15, 2006
- PMDA, Industry to Exchange Opinions
May 15, 2006
- NEW PRODUCTS
May 15, 2006
- REGULATORY NEWS IN BRIEF
May 15, 2006
- NBI Aims to Double Sales to \200 Bil. By 2010
May 15, 2006
- Drug Discovery & Development Summit Japan
May 15, 2006
- COMMENTARY 3 articles
May 15, 2006
- LDP to Take Initiative to Promote
May 15, 2006
- TeGenero Incident Victims
May 15, 2006
- BUSINESS NEWS IN BRIEF
May 8, 2006
- JPMA
May 8, 2006
- Approval of 32 New Drug Products Notified
May 8, 2006
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…